Dr. Raje discusses results from a large phase III trial comparing denosumab with zoledronic acid for delaying the time to a skeletal-related complication in patients with myeloma.
Noopur Raje, MD: Denosumab Versus ZA for Myeloma-Related Bone Disease
Recent Articles
Treatment With Four Cycles of R-CHOP Is Non-Inferior to Six Cycles in Some Aggressive...
For patients with aggressive B-cell non-Hodgkin lymphoma (NHL) and a favorable prognosis, treatment with four cycles of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and...
Avadomide Shows Promising Clinical Activity and Tolerability in Relapsed/Refractory DLBCL
Avadomide monotherapy demonstrated preliminary clinical efficacy in patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL), according to results from a phase I...
Editor’s Corner: The China Conundrum
As I begin writing this editorial, nanoscience expert Charles Lieber, PhD, Chair of Harvard University’s Department of Chemistry and Chemical Biology, is sitting in...
Merck to Shed Women’s Health Products, Shift Focus to Cancer Drugs
As part of an effort to focus on cancer drugs, vaccines, and animal health, drug manufacturer Merck plans to spin off $6.5 billion in...
Venture Capital Firm Directs $750 Million to Health and Biotech Start-Ups
Silicon Valley venture capital firm Andreessen Horowitz has launched Biofund III, a $750 million fund directed at health and biology start-ups like EQRx, which...
Current Issue
February 2020, Volume 6, Issue 3
This issue examines the high price of treating hemophilia, asks whether CAR T-cell therapies are worth the cost, and more.
